News & Updates
Showing Oncology articles
Showing
Nivolumab bests ipilimumab in head-to-head melanoma trial
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Enzalutamide-ADT a win for biochemically recurrent prostate cancer
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.
Enzalutamide-ADT a win for biochemically recurrent prostate cancer
27 Oct 2025
ALEX final OS analysis: Alectinib superior to crizotinib in 1L ALK+ NSCLC
Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).
ALEX final OS analysis: Alectinib superior to crizotinib in 1L ALK+ NSCLC
26 Oct 2025
What is the most cost-effective CRC screening strategy in Asians?
Faecal immunochemical test (FIT) positive result followed by artificial intelligence (AI)–assisted colonoscopy represents the most cost-effective colorectal cancer (CRC) screening strategy in an Asian population, according to a study from the Chinese University of Hong Kong (CUHK).
